PB2126: R-CPOP AS FIRST LINE TREATMENT FOR DLBCL PATIENTS WITH SIGNIFICANT REDUCED LVEF OR HIGH RISK OF ANTHRACYCLINE INDUCED CARDIOTOXICITY. (23rd June 2022)

Record Type:
Journal Article
Title:
PB2126: R-CPOP AS FIRST LINE TREATMENT FOR DLBCL PATIENTS WITH SIGNIFICANT REDUCED LVEF OR HIGH RISK OF ANTHRACYCLINE INDUCED CARDIOTOXICITY. (23rd June 2022)
Main Title:
PB2126: R-CPOP AS FIRST LINE TREATMENT FOR DLBCL PATIENTS WITH SIGNIFICANT REDUCED LVEF OR HIGH RISK OF ANTHRACYCLINE INDUCED CARDIOTOXICITY
Authors:
Lorenz, K.
Strüßmann, T.
Trepel, M.
Illerhaus, G.
Pelz, H.
Scholz, C.
Duyster, J.
Marks, R.
Abstract:
Is Part Of:
HemaSphere. Volume 6(2022)Supplement 3
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Issue Display:
Volume 6, Issue 3 (2022)
Year:
2022
Volume:
6
Issue:
3
Issue Sort Value:
2022-0006-0003-0000
Page Start:
1997
Page End:
1998
Publication Date:
2022-06-23
Subjects:
Hematology -- Periodicals
616.15005
Journal URLs:
https://journals.lww.com/hemasphere/pages/default.aspx ↗
http://journals.lww.com/pages/default.aspx ↗
DOI:
10.1097/01.HS9.0000851336.89795.74 ↗
Languages:
English
ISSNs:
2572-9241
Deposit Type:
Legaldeposit
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:
22681.xml